Kwality Pharmaceuticals Limited Q4 FY26 results deck summary

Results deck of 19 May 2026, summarised by AI from the filing.

Kwality Pharmaceuticals reported FY26 revenue ₹503.1 cr and PAT ₹67.4 cr, and targets FY27 revenue of ₹650+ cr with 25% EBITDA margin.

Key takeaways

1. FY26 results FY26 revenue ₹503.1 cr (FY25: ₹370.2 cr, +36%), EBITDA ₹118.3 cr (FY25: ₹80.4 cr, +47%), PAT ₹67.4 cr (FY25: ₹39.8 cr, +72%).
2. Execution risk Unit 6 hormone facility is under construction with equipment installation at 30% and team recruitment at 5%.

Original filing on BSE

Kwality Pharmaceuticals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (10 Aug 2026), Results deck (10 Aug 2026)
• Q4 FY26: Earnings call (19 May 2026), Results deck (19 May 2026)
• Q3 FY26: Results deck (12 Feb 2026)
• Q4 FY25: Results deck (5 Jun 2025)